TrialsgrambetaRCTs are beautiful

LEADER

2016

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

In 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.

Result

Efficacy: CV death, MI or strokeHR 0.87

Below 1 favours liraglutide, above 1 favours placebo.

Event rates
Absolute difference
1.9 points

The absolute difference is derived from the event rates.

Also reported: CV and all-cause mortality reduced.

Original publication
Subtopic
GLP-1 RA
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Marso SP, et al. N Engl J Med. 2016;375(4):311-322.doi 10.1056/NEJMoa1603827

Discussion & critique

Established the cardiovascular benefit of GLP-1 receptor agonists: roughly a 14 % MACE reduction is now regarded as a class effect.

Discussed in podcasts